• 5-HT3 Antagonists Modulate Renal OCT2/MATE1: In Vitro Insigh

  2026-07-05

  This study systematically evaluates how five antiemetic 5-HT3 receptor antagonists, including tropisetron, inhibit renal organic cation transporters OCT2 and MATE1 in vitro. The findings reveal differential transporter inhibition, with implications for drug-drug interactions and pharmacokinetics in serotonin receptor signaling research.

• Technical Use of Angiotensin I/II (1-5) in RAS Research

  2026-07-04

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for precise modeling of the renin-angiotensin system in hypertension and renal studies. It is designed for protocols focused on blood pressure regulation and aldosterone signaling, but should not be used outside cardiovascular or renal research contexts due to its specific biochemical and solubility properties.

• Regorafenib Suppresses Melanoma via RRM2 and ERK/E2F3 Pathwa

  2026-07-03

  Recent research uncovers that Regorafenib (BAY 73-4506) exerts potent antitumor effects in melanoma by targeting RRM2 and the ERK/E2F3 signaling pathway. These findings highlight a mechanistic advance and suggest new experimental routes for cancer biology research targeting tumor progression and metastasis.

• 4-Hydroxytamoxifen: Technical Workflow Guide for Lab Researc

  2026-07-03

  4-Hydroxytamoxifen addresses the need for a high-purity, DMSO-soluble estrogen receptor modulator in precise research settings, especially in breast and prostate cancer studies and cardiac myocyte assays. It is not compatible with ethanol or aqueous-based protocols, and correct storage and handling are critical to maintain reproducibility.

• BGJ398 (NVP-BGJ398): Optimizing FGFR Signaling Research Work

  2026-07-02

  BGJ398 (NVP-BGJ398) empowers oncology and developmental biology labs to precisely dissect FGFR signaling, with proven potency and selectivity in both cancer and morphogenesis models. This guide delivers protocol-driven enhancements, troubleshooting strategies, and translational assay insights rooted in recent comparative research.

• Stattic and STAT3 Inhibition: Molecular Insights and Transla

  2026-07-02

  Explore how Stattic, a potent STAT3 inhibitor, uniquely advances cancer biology, radiosensitization, and apoptosis induction. This article provides in-depth mechanisms, protocol nuances, and new insights for assay optimization.

• Annexin V, Human Recombinant: Precision Phosphatidylserine B

  2026-07-01

  Explore how Annexin V, a leading phosphatidylserine binding protein, enables nuanced apoptosis assays and innovative cell death investigations. This article delivers deep scientific insights and practical protocols, distinguishing itself with advanced applications and reference-driven guidance.

• O-GlcNAcylation Regulates Ferroptosis and Syncytialization i

  2026-07-01

  This study reveals that O-GlcNAc modification, via stabilization of the E3 ligase HUWE1, orchestrates transferrin receptor 1 (TfR1) degradation, thereby suppressing ferroptosis and rescuing trophoblast syncytialization defects in preeclampsia. The findings clarify a mechanistic link between O-GlcNAcylation, iron homeostasis, and placental pathology, suggesting new therapeutic angles for pregnancy complications.

• BX795: Precision PDK1 Inhibition for Translational Impact

  2026-06-30

  This thought-leadership article explores how BX795, a potent PDK1 inhibitor, enables translational researchers to dissect PI3K/Akt/mTOR and innate immune pathways with unprecedented precision. By integrating mechanistic insights, recent advances in in vitro drug evaluation, and strategic workflow guidance, we illuminate best practices for leveraging BX795 in cancer and immunology research—and chart new territory beyond conventional product pages.

• ALDH2 Activation Promotes Cardiomyocyte Proliferation in Hea

  2026-06-30

  A recent study demonstrates that ALDH2 activation significantly extends the proliferative window of cardiomyocytes and delays the progression of pressure overload-induced heart failure in mice. These findings highlight the therapeutic potential of ALDH2 activators for cardiac regeneration and inform future research on mechanisms of cardioprotection and aldehyde detoxification.

• Miltefosine Promotes Neutrophil Differentiation via Ras/MEK/

  2026-06-29

  The reference study reveals that Miltefosine, previously recognized for PI3K/Akt pathway inhibition, can activate the Ras/MEK/ERK cascade to restore neutrophil differentiation and bone marrow recovery in leukopenia models. This dual-pathway modulation highlights Miltefosine’s potential as a mechanistically distinct therapeutic agent for hematological disorders.

• GPNMB-Based Multimodal Model Predicts ESCC Immunotherapy Res

  2026-06-29

  This study develops and clinically validates a multimodal model integrating circulating GPNMB, tumor microenvironment signatures, and clinical-pathological data to predict immunotherapy response in esophageal squamous cell carcinoma (ESCC). The mechanistic discovery of sGPNMB-driven CD8+ T cell exhaustion provides a new avenue for patient stratification and tailored immunotherapy.

• Tetrahydromagnolol: Optimizing Peripheral CB2 Receptor Agoni

  2026-06-28

  Tetrahydromagnolol stands out as a highly selective peripheral CB2 receptor agonist, enabling unparalleled precision in cannabinoid signaling and anti-inflammatory research. This guide delivers actionable protocols, troubleshooting tips, and strategic context for leveraging Tetrahydromagnolol in metastasis and GPCR-driven migration studies.

• EZH2 Modulation by Salidroside Protects Endothelial Cells fr

  2026-06-27

  The referenced study uncovers how salidroside (SAL) protects human endothelial cells from hydrogen peroxide-induced dysfunction by targeting the epigenetic regulator EZH2. By modulating key autophagy and inflammatory pathways, SAL demonstrates a mechanistic approach to mitigating endothelial dysfunction, advancing the understanding of vascular protection under oxidative stress.

• Ceftolozane/Tazobactam: Advances in β-Lactam Therapy for MDR

  2026-06-26

  The reference study introduces ceftolozane/tazobactam as a new cephalosporin/β-lactamase inhibitor combination with notable activity against resistant Gram-negative bacteria, especially Pseudomonas aeruginosa and ESBL-producing Enterobacteriaceae. Its pharmacokinetic and pharmacodynamic advantages position it as a promising candidate for complicated intraabdominal and urinary tract infections, addressing gaps in current antibacterial strategies.

446 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page